PCMC
CRSP icon

Planning Capital Management Corporation’s CRISPR Therapeutics CRSP Stock Holding History

Planning Capital Management Corporation’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		$1.93K Buy
41
+40
+4,000% +$2.03K ﹤0.01% 591
2024
Q2 		$55 Buy
+1
New +$58 ﹤0.01% 681

Other funds holding CRSP

Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Planning Capital Management Corporation's CRSP Position: Q3 2024 in Review

Planning Capital Management Corporation increased its CRISPR Therapeutics (CRSP) stake by 4,000% in Q3 2024, buying an estimated $2.03K and bringing the position to 41 shares worth $1.93K. The position accounts for ﹤0.01% of the portfolio, ranked #591.

Planning Capital Management Corporation first reported a position in CRSP in Q2 2024 and has held it in 2 quarters since. 416 funds tracked by Wall St. Rank hold CRSP as of Q3 2024.

  • Planning Capital Management Corporation held 41 shares of CRISPR Therapeutics worth $1.93K as of Q3 2024.
  • Planning Capital Management Corporation bought 40 CRISPR Therapeutics shares in Q3 2024, an estimated $2.03K.
  • CRISPR Therapeutics made up ﹤0.01% of Planning Capital Management Corporation's portfolio in Q3 2024, its #591 holding.
  • Planning Capital Management Corporation first reported a position in CRISPR Therapeutics in Q2 2024 and has held it in 2 quarters since.
  • 416 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q3 2024.

Based on Planning Capital Management Corporation's 13F filing for Q3 2024, filed 6 Nov 2024.